Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders.

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Shares of Novo Nordisk climbed nearly 7% on Wednesday after the company said sales of its obesity drug Wegovy are expected to ...

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...

Caremark negotiated an undisclosed lower net price for Wegovy over Zepbound on its standard formularies, offering savings on Novo Nordisk's drug to clients that opt into those plans. Get top local ...

Novo Nordisk will continue offering its top-selling insulin brand, Mixtard, in vial form in India, despite phasing out Penfill cartridges. This decision follows concerns about the discontinuation ...